DE10399006I2 - Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung. - Google Patents

Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.

Info

Publication number
DE10399006I2
DE10399006I2 DE2003199006 DE10399006C DE10399006I2 DE 10399006 I2 DE10399006 I2 DE 10399006I2 DE 2003199006 DE2003199006 DE 2003199006 DE 10399006 C DE10399006 C DE 10399006C DE 10399006 I2 DE10399006 I2 DE 10399006I2
Authority
DE
Germany
Prior art keywords
preparation
tetracyclic derivatives
tetracyclic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2003199006
Other languages
English (en)
Other versions
DE10399006I1 (de
Inventor
Alain Claude-Marie Daugan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10399006(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of DE10399006I1 publication Critical patent/DE10399006I1/de
Publication of DE10399006I2 publication Critical patent/DE10399006I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE2003199006 1994-01-21 1995-01-19 Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung. Active DE10399006I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds
PCT/EP1995/000183 WO1995019978A1 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use

Publications (2)

Publication Number Publication Date
DE10399006I1 DE10399006I1 (de) 2003-07-31
DE10399006I2 true DE10399006I2 (de) 2004-05-06

Family

ID=10749089

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2003199006 Active DE10399006I2 (de) 1994-01-21 1995-01-19 Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE69503753T Expired - Lifetime DE69503753T2 (de) 1994-01-21 1995-01-19 Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69503753T Expired - Lifetime DE69503753T2 (de) 1994-01-21 1995-01-19 Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung

Country Status (49)

Country Link
US (5) US5859006A (de)
EP (1) EP0740668B1 (de)
JP (3) JP3808095B2 (de)
KR (1) KR100357411B1 (de)
CN (2) CN1045777C (de)
AP (1) AP556A (de)
AT (1) ATE169018T1 (de)
AU (2) AU689205B2 (de)
BG (1) BG62733B1 (de)
BR (1) BR9506559C8 (de)
CA (1) CA2181377C (de)
CO (1) CO4340684A1 (de)
CZ (1) CZ286566B6 (de)
DE (2) DE10399006I2 (de)
DK (1) DK0740668T3 (de)
EE (1) EE03231B1 (de)
EG (1) EG25852A (de)
ES (1) ES2122543T3 (de)
FI (1) FI113176B (de)
GB (1) GB9401090D0 (de)
HK (1) HK1013286A1 (de)
HR (1) HRP950023B1 (de)
HU (1) HU222494B1 (de)
IL (1) IL112384A (de)
IN (1) IN183942B (de)
IS (1) IS1888B (de)
LU (1) LU91017I2 (de)
LV (1) LV11690B (de)
MA (1) MA23433A1 (de)
MX (1) MX9602904A (de)
MY (1) MY114663A (de)
NL (1) NL300124I2 (de)
NO (2) NO306465B1 (de)
NZ (1) NZ279199A (de)
OA (1) OA10584A (de)
PE (1) PE49495A1 (de)
PL (1) PL179744B1 (de)
RO (1) RO117794B1 (de)
RU (1) RU2142463C1 (de)
SA (1) SA95150475B1 (de)
SG (1) SG49184A1 (de)
SI (1) SI0740668T1 (de)
SK (1) SK280879B6 (de)
SV (1) SV1995000002A (de)
TN (1) TNSN95004A1 (de)
TW (1) TW378210B (de)
UY (1) UY23893A1 (de)
WO (1) WO1995019978A1 (de)
ZA (1) ZA95424B (de)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6046216A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
TR199802282T2 (xx) 1996-05-10 1999-03-22 Icos Corporation Karbolin t�revleri.
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
CA2294480C (en) 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6211220B1 (en) 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
JP2002539247A (ja) 1999-03-24 2002-11-19 ハーバー ブランチ オーシャノグラフィック インスティテューション インク． マンズアミンの抗炎症作用の使用
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
SK287869B6 (sk) * 1999-08-03 2012-02-03 Icos Corporation Beta-carboline pharmaceutical compositions
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
SK4562002A3 (en) 1999-10-11 2003-04-01 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6562830B1 (en) 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
MXPA02012076A (es) * 2000-06-07 2003-06-06 Lilly Icos Llc Compuestos quimicos.
CA2412594C (en) * 2000-06-23 2009-03-17 Lilly Icos Llc Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives
AU2001263278A1 (en) * 2000-06-23 2002-01-08 Lilly Icos Llc Cyclic gmp-specific phosphodiesterase inhibitors
CA2413510C (en) * 2000-06-26 2007-12-11 Lilly Icos Llc Condensed pyrazindione derivatives
AU2001278480A1 (en) * 2000-07-24 2002-02-05 Bayer Crop Science Ag Biphenyl carboxamides
CA2423357C (en) * 2000-08-02 2008-05-27 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2244659T3 (es) * 2000-10-02 2005-12-16 Lilly Icos Llc Derivados de hexahidropirazino (1'2':1,6)-pirido(3,4-b)indol-1,4-diona para el tratamiento de trastornos cardiovasculares y disfuncion erectil.
ES2248399T3 (es) 2000-10-02 2006-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
EP1211313A3 (de) * 2000-11-01 2003-04-23 Pfizer Limited Modulation der PDE11A-AKtivität
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
JP4107421B2 (ja) 2000-11-06 2008-06-25 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅ５阻害剤としてのインドール誘導体
ES2278956T3 (es) * 2001-04-25 2007-08-16 Lilly Icos Llc Derivados de carbolina como inhibidores de fosfodiesterasa 5 (pde5) para el tratamiento de enfermedades cardiovasculares y de la disfuncion erectil.
MXPA03011082A (es) 2001-06-05 2004-07-08 Lilly Icos Llc Derivados de pirazino-1',2': 1,6-prirido-3,4-b-indol-1,4-diona.
ATE360422T1 (de) * 2001-06-05 2007-05-15 Lilly Icos Llc Tetrazyklische verbindungen als pde5-inhibitoren
US6992192B2 (en) 2001-06-05 2006-01-31 Lilly Icos Llc. Carboline derivatives as PDE5 inhibitors
WO2003000691A1 (en) * 2001-06-21 2003-01-03 Lilly Icos Llc Carboline derivatives as pdev inhibitors
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
MXPA04004370A (es) * 2001-11-09 2004-08-11 Schering Corp Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
CN1280292C (zh) * 2001-11-14 2006-10-18 奥索-麦克尼尔药品公司 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
PL374198A1 (en) * 2002-05-23 2005-10-03 Pfizer Inc. Novel combination
EP1719772A1 (de) 2002-05-31 2006-11-08 Schering Corporation Verfahren zur Herstellung von Xanthin Phosphodiesterase v Inhibitoren und deren Vorstufen
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
KR100937915B1 (ko) * 2002-07-31 2010-01-21 릴리 아이코스 엘엘씨 변형된 픽텟-스펭글러 반응 및 그것으로부터 제조된생성물
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EP1572173B1 (de) 2002-12-13 2010-04-28 Warner-Lambert Company LLC Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
EP1620437B1 (de) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
RS52730B (sr) * 2003-05-22 2013-08-30 Takeda Gmbh Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor
EP1644021B1 (de) * 2003-06-13 2012-08-22 Ironwood Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1699436A2 (de) * 2003-12-12 2006-09-13 Myogen, Inc. Enoximon-formulierungen und ihre verwendung bei der behandlung von herzhypertrophy und herzinsuffizienz
WO2005068464A2 (en) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2560528A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
ATE417849T1 (de) 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
WO2005116030A1 (en) * 2004-05-31 2005-12-08 Matrix Laboratories Ltd A process for the preparation of tadalafil
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
EP2216329A1 (de) * 2004-10-28 2010-08-11 Dr. Reddy's Laboratories Ltd. Verfahren zur Herstellung von Tadalafil
CA2582092A1 (en) * 2004-11-02 2006-05-11 Teva Pharmaceutical Industries Ltd. Tadalafil crystal forms and processes for preparing them
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
PT1829874E (pt) 2004-12-22 2014-04-10 Ono Pharmaceutical Co Composto tricíclico e sua utilização
WO2006091980A1 (en) * 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Process of purifying tadalafil
CA2599378A1 (en) 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Tadalafil having a large particle size and a process for preparation thereof
MX2007009707A (es) * 2005-02-25 2007-09-12 Teva Pharma Proceso para sintetizar tadalafil.
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
MX2007012607A (es) * 2005-04-12 2008-01-11 Teva Pharma Preparacion de intermedios de tadalafil.
ME01609B (me) 2005-04-19 2014-09-20 Takeda Gmbh Roflumilast za liječenje pulmonarne hipertenzije
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
KR100939890B1 (ko) 2005-05-12 2010-01-29 화이자 인코포레이티드 Ｎ-[1-(2-에톡시에틸)-5-(Ｎ-에틸-Ｎ-메틸아미노)-7-(4-메틸피리딘-2-일-아미노)-1Ｈ-피라졸로[4,3-ｄ]피리미딘-3-카르보닐]메탄술폰아미드의 무수 결정 형태
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
WO2007016361A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
WO2007033239A2 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007100387A2 (en) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Process for preparing tadalafil
EP2218442A1 (de) 2005-11-09 2010-08-18 CombinatoRx, Inc. Verfahren, Zusammensetzungen und Kits zur Behandlung von ophthalmologischen Erkrankungen
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007110734A1 (en) * 2006-03-24 2007-10-04 Glenmark Pharmaceuticals Limited Process for the preparation of tadalafil
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
BRPI0715423A2 (pt) 2006-07-21 2013-07-02 Novartis Ag formulaÇÕes para Éteres de benzimidazolil piridila
EA200900264A1 (ru) 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2008036678A2 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
HUE025355T2 (en) 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2120570B1 (de) 2007-02-12 2012-05-16 DMI Biosciences, Inc. Behandlung frühzeitiger comorbid-ejakulation und erektiler dysfunktion
NZ579170A (en) 2007-02-12 2012-05-25 Dmi Biosciences Inc Reducing side effects of tramadol
WO2008103470A2 (en) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
CA2685184A1 (en) * 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Solid dosage forms
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
EP2170880B1 (de) 2007-06-29 2012-08-15 Ranbaxy Laboratories Limited Verfahren zur herstellung von zwischenprodukten tetracyclischer verbindungen
EP2033962A1 (de) * 2007-08-22 2009-03-11 4Sc Ag Tetrazyclische Indolopyridinderivate als EG5-Hemmer
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
ITMI20080285A1 (it) * 2008-02-22 2009-08-23 Endura Spa Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
EP2107059A1 (de) * 2008-03-31 2009-10-07 LEK Pharmaceuticals D.D. Umwandlung von Tryptophan in ß-Carbolinderivate
PL385356A1 (pl) 2008-06-03 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania tadalafilu
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2181997A1 (de) 2008-10-30 2010-05-05 Chemo Ibérica, S.A. Verfahren zur Herstellung von Tadalafil
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
EP2379076B1 (de) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase-hemmer und ihre verwendungen
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2400848A4 (de) 2009-02-26 2012-07-25 Thar Pharmaceuticals Inc Kristallisierung von pharmazeutischen verbindungen
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
NZ610012A (en) 2010-10-15 2015-05-29 Gilead Sciences Inc Compositions and methods of treating pulmonary hypertension
ES2541421T3 (es) 2011-02-10 2015-07-20 Interquim, S.A. Procedimiento de obtención de compuestos derivados de tetrahidro-ß-carbolina
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
US20120123124A1 (en) * 2011-04-22 2012-05-17 Drug Process Licensing Associates, LLC Manufacturing process for Tadalafil from racemic or L-tryptophan
CN102180876B (zh) * 2011-05-28 2016-05-18 浙江华海药业股份有限公司 一种他达那非晶型i的制备方法
EP2535049A1 (de) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil zur Behandlung von Demenz
CN102367253B (zh) * 2011-09-20 2016-04-06 浙江华海药业股份有限公司 一种制备他达拉非晶型a的方法
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2013109230A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
WO2013109227A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
WO2013109223A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
JP5941558B2 (ja) 2012-02-28 2016-06-29 株式会社ソウル製薬Ｓｅｏｕｌ Ｐｈａｒｍａ． Ｃｏ．， Ｌｔｄ． シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
ES2903151T3 (es) 2012-12-04 2022-03-31 Aribio Inc Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
WO2014100733A1 (en) 2012-12-21 2014-06-26 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
AP2015008670A0 (en) 2013-02-21 2015-08-31 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
CN103232451A (zh) * 2013-05-14 2013-08-07 张家港威胜生物医药有限公司 一种他达那非的简易制备工艺
WO2015009930A2 (en) 2013-07-17 2015-01-22 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
EP3082428A4 (de) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5-inhibitorpulverformulierungen und zugehörige verfahren
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
EP2962684A1 (de) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Im mund zerfallende formulierungen von tadalafil
WO2016001143A1 (en) 2014-06-30 2016-01-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of tadalafil
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
SI3466951T1 (sl) 2014-07-23 2022-05-31 Krka, D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
CA2987109C (en) * 2015-06-26 2020-07-07 Chongqing University of Arts and Sciences 6-(benzo[d][1,3]dioxol-5-yl)-2-substituted-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6h,7h)-dione derivatives as phosphodiesterase type-5 inhibitors
CN105541835B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
CN105541840B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 关键中间体及其合成方法和在制备他达拉非方面的应用
RU2019121646A (ru) 2016-12-14 2021-01-15 Респира Терапьютикс, Инк. Способы и композиции для лечения легочной гипертензии и других заболеваний легких
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
RU2692764C1 (ru) 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила
CN111995658B (zh) * 2019-05-27 2022-08-02 首都医科大学 Ldv修饰的五环哌嗪二酮及其制备和应用
CA3144770A1 (en) 2019-07-15 2021-01-21 Biolab Sanus Farmaceutica Ltda Stereoisomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indol-3-yl)-6,7-dihydro-3h-oxazol[3,4-a]pyrazine-5,8-dione and use thereof as an antitumor agent and phosphodiesterase enzyme inhibitor
CN110606847A (zh) * 2019-07-30 2019-12-24 中国医药集团总公司四川抗菌素工业研究所 一种他达拉非顺式中间体的制备方法及其应用
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
EP0357122A3 (de) * 1988-08-29 1991-10-23 Duphar International Research B.V Verwendung von Beta-Carbolinen und deren bio-isosterischen Benzofuran- und Benzothiophenanalogen zur Herstellung eines Arzneimittels mit cytostatischer Wirkung
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance

Also Published As

Publication number Publication date
US6369059B1 (en) 2002-04-09
DK0740668T3 (da) 1999-05-03
ZA95424B (en) 1995-09-27
CA2181377C (en) 2002-05-28
PE49495A1 (es) 1996-01-10
LU91017I2 (fr) 2003-05-26
EP0740668B1 (de) 1998-07-29
AP556A (en) 1996-11-07
ES2122543T3 (es) 1998-12-16
JP2004217674A (ja) 2004-08-05
FI962927A0 (fi) 1996-07-19
PL179744B1 (pl) 2000-10-31
US20020119976A1 (en) 2002-08-29
DE69503753D1 (de) 1998-09-03
JPH09508113A (ja) 1997-08-19
MY114663A (en) 2002-12-31
DE69503753T2 (de) 1999-01-21
IL112384A0 (en) 1995-03-30
HRP950023A2 (en) 1998-04-30
CA2181377A1 (en) 1995-07-27
PL315559A1 (en) 1996-11-12
GB9401090D0 (en) 1994-03-16
IS1888B (is) 2003-09-01
BR9506559C8 (pt) 2020-07-07
FI113176B (fi) 2004-03-15
HRP950023B1 (en) 2000-10-31
HUT74943A (en) 1997-03-28
MX9602904A (es) 1997-12-31
IS4252A (is) 1995-07-22
NO2003002I1 (no) 2003-01-22
AU689205B2 (en) 1998-03-26
HK1013286A1 (en) 1999-08-20
MA23433A1 (fr) 1995-10-01
SA95150475B1 (ar) 2005-07-31
TW378210B (en) 2000-01-01
NO306465B1 (no) 1999-11-08
IN183942B (de) 2000-05-20
US6025494A (en) 2000-02-15
TNSN95004A1 (fr) 1996-02-06
JP3808095B2 (ja) 2006-08-09
JP2009102386A (ja) 2009-05-14
BG62733B1 (bg) 2000-06-30
HU222494B1 (hu) 2003-07-28
US6127542A (en) 2000-10-03
SV1995000002A (es) 1995-10-04
CO4340684A1 (es) 1996-07-30
RU2142463C1 (ru) 1999-12-10
AU1574895A (en) 1995-08-08
CN1143963A (zh) 1997-02-26
AU707055B2 (en) 1999-07-01
DE10399006I1 (de) 2003-07-31
RO117794B1 (ro) 2002-07-30
LV11690A (lv) 1997-02-20
IL112384A (en) 1998-08-16
EP0740668A1 (de) 1996-11-06
ATE169018T1 (de) 1998-08-15
NO963015D0 (no) 1996-07-19
SK94096A3 (en) 1997-04-09
OA10584A (en) 2002-08-26
CN1070492C (zh) 2001-09-05
CN1224720A (zh) 1999-08-04
NL300124I2 (nl) 2003-11-03
EE03231B1 (et) 1999-10-15
WO1995019978A1 (en) 1995-07-27
NO963015L (no) 1996-09-09
SI0740668T1 (en) 1999-02-28
US5859006A (en) 1999-01-12
NO2003002I2 (no) 2005-03-21
HU9601982D0 (en) 1996-09-30
EG25852A (en) 2012-09-10
AP9500712A0 (en) 1995-01-31
CZ211696A3 (en) 1997-06-11
CZ286566B6 (cs) 2000-05-17
SK280879B6 (sk) 2000-08-14
LV11690B (en) 1997-06-20
BR9506559A (pt) 1997-10-28
NL300124I1 (nl) 2003-07-01
CN1045777C (zh) 1999-10-20
FI962927A (fi) 1996-07-19
US6784179B2 (en) 2004-08-31
BG100727A (bg) 1997-02-28
NZ279199A (en) 1998-01-26
JP4347125B2 (ja) 2009-10-21
AU7391298A (en) 1998-08-20
SG49184A1 (en) 1998-05-18
KR100357411B1 (ko) 2003-02-05
UY23893A1 (es) 1995-07-11

Similar Documents

Publication Publication Date Title
DE10399006I2 (de) Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE60033028D1 (de) 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE69925145D1 (de) 2-aminothiazolederivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE69529934T2 (de) Erythromycin-Derivate, Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
DE69508762T2 (de) Quaternäre ammoniumderivate, verfahren zu ihrer herstellung und ihre verwendung als oberflächenaktive verbindungen
DE59707976D1 (de) Neue guanidinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69706690D1 (de) Acryloyl-substituierte distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor- und antivirale mittel
ATE203011T1 (de) Distamycin derivate, verfahren zu ihrer herstellung sowie ihre verwendung als antitumor und antiviral wirkstoffe
DE59802412D1 (de) Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE69108356T2 (de) Hydrazonderivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE69832784D1 (de) Fluorpolymere, verfahren zu ihrer herstellung und ihre verwendung
DE845495T1 (de) Zellulosepartikeln, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59609207D1 (de) Farbstoffmischungen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59800568D1 (de) Benzoxazindionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE209212T1 (de) Aromatische ribose-substituierte derivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel
DE59608892D1 (de) Iminooxyphenylessigsäurederivate, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
DE59108884D1 (de) Triphendioxazinverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69732570D1 (de) Sulfonsäureester-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE69107143D1 (de) 2,2,3-Trimethylcyclopentenylaceton-Derivate, ihre organoleptische Verwendung und Verfahren zu ihrer Herstellung.
DE69506944D1 (de) 1-Phenyl-1-cyano-C5-C7-Alkane, ihre organoleptische Verwendung und Verfahren zu deren Herstellung
DE59700950D1 (de) 5-Z-Octenylester, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59911949D1 (de) Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
DE69112987T2 (de) Polyhalogenphthalocyanine, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE69127797T2 (de) Acylaminopyridincarboxamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide
DE69206940D1 (de) 2-Pyridon-2-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide